Captor Therapeutics SA
WSE:CTX
Captor Therapeutics SA
Research & Development
Captor Therapeutics SA
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Captor Therapeutics SA
WSE:CTX
|
Research & Development
-zł37.7m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
M
|
MLP Group SA
WSE:MLG
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lokum Deweloper SA
WSE:LKD
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
CFI Holding SA
WSE:CFI
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
Develia SA
WSE:DVL
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Cavatina Holding SA
WSE:CAV
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Captor Therapeutics SA
Glance View
Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
See Also
What is Captor Therapeutics SA's Research & Development?
Research & Development
-37.7m
PLN
Based on the financial report for Dec 31, 2024, Captor Therapeutics SA's Research & Development amounts to -37.7m PLN.
What is Captor Therapeutics SA's Research & Development growth rate?
Research & Development CAGR 5Y
-21%
Over the last year, the Research & Development growth was 38%. The average annual Research & Development growth rates for Captor Therapeutics SA have been -30% over the past three years , -21% over the past five years .
